

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/CD0852E9ADAEN.html>

Date: March 2018

Pages: 31

Price: US\$ 3,500.00 (Single User License)

ID: CD0852E9ADAEN

Abstracts

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Pipeline Review, H1 2018

SUMMARY

According to the recently published report 'Cathepsin B - Pipeline Review, H1 2018'; Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Cathepsin B (CatB) is an enzymatic protein belonging to the peptidase. It promotes hydrolysis of proteins with broad specificity for peptide bonds. It cleaves -Arg-Arg-|-Xaa bonds in small molecule substrates. In addition to being an endopeptidase, shows peptidyl-dipeptidase activity, liberating C-terminal dipeptides.

The report 'Cathepsin B - Pipeline Review, H1 2018' outlays comprehensive information on the Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase 0, Preclinical and Discovery stages are 1, 3 and 1 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Immunology and Infectious Disease which include indications Alzheimer's Disease, Autoimmune Disorders, Breast Cancer, Cancer Pain, Ebolavirus Infections (Ebola Hemorrhagic Fever), Glioblastoma Multiforme (GBM), Liver Fibrosis, Neuropathic Pain, Pancreatic Cancer, Primary Biliary Cirrhosis and Traumatic Brain Injury.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)

The report reviews Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope

Contents

Introduction

Global Markets Direct Report Coverage

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Overview

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Companies

Involved in Therapeutics Development

ALSP Inc

Oncomatrix Biopharma SL

Phelix Therapeutics LLC

Virobay Inc

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Drug Profiles

ALP-496 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CIBP-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit Cathepsin B for Ebola Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMTX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Cathepsin B for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-285 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-825 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Dormant Products

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Product Development Milestones

Featured News & Press Releases

Apr 19, 2016: American Life Science Pharmaceuticals Obtains Patent

Jan 25, 2016: ALSP invited to Give Oral Presentation at the Keystone TBI Conference
January 25-27 in Santa Fe, New Mexico

Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by ALSP Inc, H1 2018
Pipeline by Oncomatrix Biopharma SL, H1 2018
Pipeline by Phelix Therapeutics LLC, H1 2018
Pipeline by Virobay Inc, H1 2018
Dormant Projects, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

ALSP Inc

Oncomatrix Biopharma SL

Phelix Therapeutics LLC

Virobay Inc

I would like to order

Product name: Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/CD0852E9ADAEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CD0852E9ADAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

